Pfizer to Build $650 Million Campus in Groton

Pfizer plans to invest $650 million in Connecticut to build a new 220,000-square-foot facility in Groton. The company announced the expansion this week, positioning the project as a key addition to its existing research and development campus.

The new building will house a manufacturing technology center. Once operational, the site will produce pharmaceutical ingredients and drug products specifically for clinical trials. Economic development organization AdvanceCT released a statement detailing the plans on Thursday.

Construction on the Groton site is scheduled to begin in 2027. Pfizer aims to have the manufacturing facility fully open by 2031. The expansion represents a major physical commitment to the state's industrial infrastructure.

This announcement arrives alongside other economic developments in the state. Eversource President Joe Nolan told investors on a Thursday call that the utility does not expect to settle its 18% rate increase request soon. Nolan stated that the company has much work to do before it can discuss a settlement with regulators. A decision on the rate case is expected in June if no agreement is reached.

In Cromwell, Mayor James Demetriades said the town will consider a six-month moratorium on data center development. This follows backlash against a proposed 550,000-square-foot project by Global Commons that uses gas fuel cells. Although city officials have not received a building permit application, a public hearing on the moratorium is set for December 3 at the local middle school.

CVS Health also announced plans to split its operations. The company will separate its healthcare business, which includes Aetna, from its 9,000 drugstores. The new CVS Pharmacy entity will handle mail pharmacy and virtual care. CVS expects to complete the separation by early 2028.

On the policy front, Governor Ned Lamont announced that federal regulators approved a state initiative to expand Medicaid coverage for people in incarceration. Starting in April 2027, eligible individuals can receive coverage 60 days before their release. The goal is to prevent gaps in medical care, mental health services, and substance use treatment during reentry.